IKT - Inhibikase Therapeutics Inc Net Assets per Single Share
Anticipation of the Phase II trial results for a Parkinson's disease drug is fueling interest in Inhibikase Therapeutics (IKT), with the current indicator standing at 1.16. This chart of the current share price reflects the dynamics of the company, which is developing a neurodegeneration therapy system via kinase inhibitors. The business relies on the precision delivery of biomaterials, while a partnership with a laboratory network ensures supply stability and high profitability.
Analytical breakdowns for inhibikase.com (IKT)
- share price and expert price forecast:
- market capitalization statistics:
- shareholders' equity book value data:
- debt burden and liquidity indicators:
Debt to Equity Inhibikase Therapeutics|IKT - Long-Term Debt to Capital Coefficient|Short-Term Debt to Equity Inhibikase Therapeutics, Inc.|IKT - Company Cumulative Debt|Debts to Book Capitalization Inhibikase Therapeutics, Inc.|IKT - Long-Term Debt Volume|Company Short-Term Debt Inhibikase Therapeutics
Basic company analysis:Inhibikase (IKT)
Book value per share reflects the company's net equity minus all liabilities, allowing the aggregate book value per security to determine the asset's fundamental basis during periods of market volatility. For Inhibikase Therapeutics (IKT), this calculated indicator demonstrates the actual tangible backing of each share, which is critical when assessing the value of a highly specialized scientific staff and long-term researcher option programs.
Competitors of Inhibikase Therapeutics
BIIB: Accounting Value per Share|Neurocrine Corp - Book Price of a Share|Regencell Bioscience (RGC) - Net Assets per Single Share|Equity per Share AXSM|ACAD (ACADIA Pharmaceuticals Inc.) - Book Value per Share|Net Asset Value per Share Xenon Pharmaceuticals Inc. XENE|Accounting Value per Share VKTX (Viking Pharma)|Book Value per Share Supernus Corp (SUPN)|Net Assets per Single Share Catalyst Pharmaceuticals CPRX|Accounting Value of a Share DNLI|HRMY - Net Assets per Single Share|Net Asset Value per Share Biohaven Ltd|AMLX: Book Value per Share|TRVI - Net Assets per Share|Net Assets per Single Share Praxis Precision Medicines|Equity per Share AVXL (anavex.com)|Book Value per Share CBLL|PRTA (Prothena Corporation) - Accounting Value of a Share|Book Value per Share ALEC (Alector)|Net Assets per Share Annexon Biosciences Inc. (ANNX)|Omeros Corp. - Book Value per Share|NGNE: Net Assets per Single Share|ACIU: Book Value per Share|VYGR - Net Assets per Share|Net Assets per Single Share Neumora Therapeutics Inc|Book Value per Share Scilex Holding Company, Inc.|Book Value per Share TVGN|Book Value per Share alphacognition.com (ACOG)|Net Assets per Single Share Cognition Therapeutics CGTX|Net Assets per Share Cassava Sciences Inc (SAVA)|Assertio Therapeutics - Book Value per Share|Net Asset Value per Share Coya Therapeutics, Inc.|VTGN (vistagen.com) - Accounting Value per Share|Ovid Therapeutics - Accounting Value of a Share|Accounting Value per Share ABOS|CRVO (CervoMed, Inc.) - Book Price of a Share|Book Value per Share ATHE|CLNN (clene.com) - Accounting Value of a Share|Book Value per Share PEPG (PepGen)|Jupiter Neurosciences, Inc. (JUNS) - Net Asset Value per Share|RLMD - Net Assets per Single Share|Accounting Value of a Share ANVS (Annovis Bio Inc)|GRCE: Book Value per Share|Firefly Neuro (AIFF) - Book Value per Share|Net Assets per Single Share ANEW Medical|NeuroSense Therapeutics, Ltd. - Share Book Value|Book Value per Share RVPH|MTVA - Net Asset Value per Share|NeurAxis, Inc - Accounting Value per Share|Book Value per Share Helius Medical Technologies, Inc. HSDT|PASG: Accounting Value per Share|Neuphoria Therapeutics Inc. - Book Price of a Share|NERV: Book Value per Share|ATHA - Net Assets per Share|ADXN (Addex Therapeutics, Ltd.) - Book Value per Share|Accounting Value per Share Alzamend (ALZN)|Net Assets per Single Share Cyclerion Therapeutics (CYCN)|Net Assets per Share protagenic.com|Book Value per Share KTTA (Pasithea Therapeutics Corp.)|Net Assets per Share Cortigent Inc (CRGT)|ATXI - Net Assets per Single Share|BCLI - Book Value per Share|CARA (Cara Therapeutics, Inc.) - Accounting Value per Share|CHRO: Book Price of a Share|Net Assets per Single Share Eliem Therapeutics, Inc.|Equity per Share ITCI (Intra-Cellular)|Book Value per Share LBPH|MRNS - Net Asset Value per Share|NKGen Biotech, Inc. - Accounting Value per Share|Book Value per Share neurobopharma.com NRBO|SAGE - Net Assets per Single Share|Accounting Value of a Share SNPX (Synaptogenix Inc.)|Trevena, Inc (TRVN) - Net Assets per Single Share|Net Asset Value per Share Vigil Neuroscience, Inc. (VIGL)|WENA (Anew Medical) - Book Value per Share|cerevel.com (CERE) - Net Assets per Share